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Abstract
The risk of hepatocellular carcinoma increases with the persistence of non-alcoholic fatty liver
disease. Triacylglycerol synthesis is initiated by glycerol-3-phosphate acyltransferase (GPAT). Of
four isoforms, GPAT1 contributes 30–50% of total liver GPAT activity, and we hypothesized that
it might influence liver susceptibility to tumorigenesis. C57Bl/6 mice deficient in GPAT1 were
backcrossed 6 times to C3H mice. After exposure to the carcinogen diethylnitrosamine (DEN) and
the tumor promoter phenobarbital, male Gpat1−/− mice, compared with controls (Gpat1+/+), had
93% fewer macroscopically visible nodules per liver at 21 weeks of age and 39% fewer at 34
weeks of age. Microscopically, control mice had increased numbers of foci of altered hepatocytes,
particularly the basophilic subtype, as well as more, and malignant, liver neoplasms than did the
Gpat1−/− mice. At 21 weeks of age, 50% (4/8) of control mice (50%) had hepatocellular adenomas
with an average multiplicity (tumors per tumor-bearing-animal) of 4.3, while none occurred in 8
Gpat1−/− mice. At 34 weeks of age, all 15 control mice (100%) had hepatocellular adenomas with
an average multiplicity of 5.2 compared to an incidence of 93% in Gpat1−/− mice and multiplicity
of 3.1. HCCs were observed in 13% of control mice and in only 6% of Gpat1−/− mice. These data
show that alterations in the formation of complex lipids catalyzed by Gpat1 reduce susceptibility
to DEN-induced liver tumorigenesis.
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Introduction
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death
worldwide, accounting for 600,000 deaths annually (World Health Organization [WHO]
2009; Parkin et al. 2005). During the past two decades, the incidence of HCC in developed
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countries has increased due to both the increased prevalence of infection with the hepatitis C
virus (El-Serag and Mason 1999; Bosch et al. 2004) and the growing numbers of obese
individuals. It has been predicted that the major causes for liver transplantation in the next
20 years will be HCC and cirrhosis resulting from non-alcoholic fatty liver disease
(NAFLD; Pillai and Rinella 2009; Schreuder et al. 2008). Non-alcoholic fatty liver disease is
defined as the accumulation of intracellular triacylglycerol (TAG) in the liver of individuals
who consume less than 20 g of alcohol/day (Neuschwander-Tetri and Caldwell 2003). The
spectrum of NAFLD ranges from benign steatosis to non-alcoholic steatohepatitis (NASH).
Non-alcoholic steatohepatitis with significant amounts of inflammation and fibrosis can
progress to cirrhosis, hepatic failure, and HCC.
Fatty liver, particularly in obese individuals, requires the action of the metabolic pathway of
triacylglycerol (TAG) biosynthesis initiated by the acylation of glycerol-3-phosphate at the
sn-1 position by glycerol-3-phosphate acyltransferase (GPAT; Coleman and Lee 2004).
GPAT is the rate limiting step in the de novo synthesis of both glycerophospholipids and
TAG (Kennedy 1961; Coleman and Lee 2004). In mammals, this reaction is catalyzed by
one of 4 GPAT isoforms (GPAT1–4), each encoded by a separate gene. GPAT isoforms
vary in their tissue expression and subcellular location. GPAT1, which is located in the outer
mitochondrial membrane, is most prominent in adipose tissue, kidney, and liver. The role of
GPAT1 in liver is of particular interest because of its high contribution (30–50%) to total
hepatic GPAT activity compared with other tissues (~10%; Hammond et al. 2002) and the
up-regulation of its expression by SREBP1c, a transcription factor regulated by insulin.
Thus, hepatic GPAT1 mRNA and activity are high under physiological conditions when an
obesogenic diet and high insulin concentrations promote TAG synthesis. Glycerol-3-
phosphate acyltransferase 1 competes with carnitine palmitoyltransferase-1 (CPT-1) for
acyl-CoAs, thereby promoting their incorporation into glycerolipids while limiting their
entry into the mitochondria where they would be oxidized (Hammond et al. 2005). This
conclusion is supported by the observation that after Gpat1−/− mice are fed a high-fat, high-
sucrose diet for 4 months, they have higher amounts of serum β-hydroxybutyrate and
hepatic acyl-carnitines, aswell as reduced hepatic content of diacylglycerol and TAG. The
importance of GPAT1 for hepatic TAG accumulation is supported by the 60% lower hepatic
TAG content in mice lacking both GPAT1 and leptin (ob/ob-Gpat1−/− mice) when compared
to mice that are deficient in leptin alone (ob/ob; Wendel et al. 2010).
Mouse strains are differentially susceptible to HCC (Diwan, Rice, and Ward 1990). In a
strain comparison study, the carcinogen DEN initiated tumor formation in all C3H mice but
in only 30% of C57Bl/6 mice, and the average number of foci of altered hepatocytes per
liver was 20- to 50-fold greater in C3H mice compared with C57Bl/6 mice (Drinkwater and
Ginsler 1986). In a comparison of spontaneous tumors and those induced with vinyl
carbamate, the prevalence of hepatocellular adenomas varied from 2.4–14.1% for
spontaneous tumors and between 22.8–72.9% in a low-dose group with the C57Bl/6 strain
being least affected and the C3H strain among the most severely affected (Takahashi et al.
2002). Furthermore, pulmonary metastases were frequently present in C3H mice. Because
mice on the C57Bl/6 strain are resistant to the induction of HCC (Diwan, Rice, and Ward
1990), we backcrossed Gpat1−/− and control mice to the liver tumor-susceptible C3H strain.
We have reported that a deficiency of GPAT1 in liver results in increased rates of fatty acid
oxidation, a 20% increase in the rate of reactive oxygen species (ROS) production, an
altered mitochondrial permeability transition, increased amounts of arachidonate (20:4ω6)
in the sn-2 position of phosphatidylcholine and phosphatidylethanolamine, and higher
amounts of the arachidonate peroxidation product, 4-hydroxynonenal in liver. The increased
oxidative stress is associated with balanced increases in both hepatocyte apoptosis and
proliferation (Hammond et al. 2007). Obesity has been associated with HCC (Park et al.
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2010) and transformed cells may develop resistance to apoptosis (Schattenberg,
Schuchmann, and Galle 2011). Because the content of TAG is low in livers from Gpat1−/−
mice and cell turnover is high, we hypothesized that the tumorigenic potential of DEN-
induced liver tumorigenesis in Gpat1−/− mice would be reduced compared to wildtype.
Methods
Animal Treatment
Gpat1−/− mice (C57Bl/6 background) were backcrossed to the HCC-susceptible C3H/
HeNCrl strain (Diwan, Rice, and Ward 1990; C3H; Charles River Laboratories) for six
generations. Control (Gpat1+/+) and Gpat1−/− mice were bred from Gpat1−/+ C3H
backcrossed mice and were housed in a pathogen-free barrier facility (12 h light/dark cycle)
in accordance with the UNC IACUC and allowed free access to water and food (Prolab
RMH 3000 SP76 chow). Mouse body weights were measured weekly. Vehicle or
diethylnitrosamine (DEN, Sigma) dissolved in PBS was injected intraperitoneally into 15.5-
day-old control and Gpat1−/− male pups at a dose of 4 mg/kg body weight. Phenobarbital
was administered ad libitum in drinking water at 500 parts per million from the age of 5
weeks to necropsy. Tissues were harvested at 8, 21, and 34 weeks of age (n = 10–15).
Individual tumors, liver, and lungs were snap frozen and stored at –80°C.
Liver Evaluation
At necropsy of 21- and 34-week-old mice, all surfaces of livers and lungs were examined for
macroscopically visible nodules. The number of nodules was recorded for each lobe of the
liver and lung. Whole lung, nodules greater than 5 mm, and one representative section of the
left, median, and caudate liver lobes was cut for histological evaluation, fixed in fresh 4%
paraformaldehyde-PBS for 24 h, dehydrated in 70% ethanol, and routinely processed and
embedded in paraffin. Paraffin embedded tissue was cut into 5-µm sections and stained with
hematoxylin and eosin. Microscopically proliferative and nonproliferative liver lesions were
evaluated by two pathologists (BS and DM) without knowledge of genetic status. Foci of
altered hepatocytes (FAH) were classified as either basophilic, eosinophilic, clear cell, or
mixed; and hepatocellular adenomas (HCA) and carcinomas (HCC) were classified using
previously published criteria (Harada et al. 1999). Briefly, FAH, which are considered
putative preneoplastic lesions (Harada et al. 1999), were identified as groups of hepatocytes
with altered tinctorial properties of the cytoplasm that range in size from less than a lobule
to sometimes greater than four lobules, with no or minimal compression of surrounding
tissues. Foci of altered hepatocytes often merge imperceptibly with surrounding
parenchyma. Mixed FAH are composed of <80% of one cell type. Hepatocellular adenomas
consisted of expansile and compressive masses of neoplastic hepatocytes, most often
without portal triads, that sometimes contained peripheral regions with varying numbers of
trabeculae, notmore than two cells wide. When trabeculae of neoplastic hepatocytes with
three cells or more were found, together with cellular pleomorphism and/or other malignant
features, the tumor was classified as an HCC.
Enzyme Activity
Livers were minced on ice and then homogenized with 10 up-and-down strokes by a motor-
driven Teflon-glass homogenizer in a buffer containing 10 mM Tris-HCl (pH 7.4), 250 mM
sucrose, 1 mM dithiothreitol, and 1 mM EDTA. The total membrane fraction was isolated
by centrifuging at 100,000 × g for 1 h at 4°C. Protein concentration was determined by the
bicinchoninic acid method (Pierce, Rockford, IL) with bovine serum albumin as the
standard. GPAT activity was assayed for 10 min at 25°C in a 200-µl reaction mix containing
75 mM Tris-HCl, pH 7.5, 4 mM MgCl2, 1 mg/ml bovine serum albumin, 1 mM
dithiothreitol, 8 mM NaF, 800 µM [3H]glycerol-3-phosphate, and 80 µM palmitoyl-CoA in
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the presence or absence of 2 mM N-ethylmaleimide (NEM). For NEM inhibition studies,
membrane protein was incubated in 1 mM NEM on ice for 15 min before its addition to the
reaction mixture. The NEM inhibition of GPAT2, 3, and 4 isoforms has been reported
previously (Lewin et al. 2004; Cao et al. 2006; Nagle et al. 2008; Chen et al. 2008). Each
reaction was initiated with 15–30 µg of protein and was proportional to the amount of time
and protein used. [3H]glycerol-3-phosphate was synthesized enzymatically from [2-3H]
glycerol (1 mCi/ml; Perkin-Elmer Life Sciences; Chang and Kennedy 1967).
RNA Quantification
Total RNA was isolated from liver with the Qiagen RNeasy Micro Tissues Kit. cDNA was
synthesized (Applied Biosystems High Capacity cDNA RT Kit), and the reaction performed
using SYBR Green (Applied Biosystems) detection with primers specific to the gene of
interest with equal amounts of cDNA (10 ng/reaction), and detected using a Taq-man
thermo-cycler (BioRad). Results were normalized to the housekeeping gene Gapdh and
expressed as arbitrary units of 2-ΔCT.
Cell Proliferation
Bromodeoxyuridine (BrdU) in the drinking water (0.2 g/L) was incorporated into
proliferating hepatocytes for 48 h before necropsy. Paraffin-embedded liver sections were
hydrolyzed in 4 N HCl and permeabilized in 0.2% pepsin (Dako) in 0.2 N HCl solution.
Immunostaining was performed with a monoclonal antibody against BrdU (Dako) diluted
1:200 in 1% bovine serum albumin in PBS. Immunohistochemical detection was performed
using a horseradish peroxidase–conjugated secondary antibody followed by development
with a 3,3′-diaminobenzidine chromogen solution (Dako). Slides were counterstained using
Mayer’s hematoxylin (Sigma). Ten BrdU-stained images from the left lobe of each liver
were randomly selected for analysis using Image Pro 7.0 software (Media Cybernetics). A
labeling index was calculated from at least 2,000 cells per liver as the number of positively
stained nuclei/total number of nuclei counted.
PPARα-Mediated Proliferative Effects
To determine whether the lipogenic pathway involving GPAT1 activity is critical for
PPARα-mediated proliferative effects, control and Gpat1−/− mice on the C57Bl/6
background were fed the PPARα ligand Wy-14,643 (Sigma) (Gonzalez and Shah 2008) in
their drinking water at 500 ppm for 1 week before tissue harvest (n = 3).
Statistical Analysis
Data are expressed as mean ± SEM. Lesion incidences were compared between control and
Gpat1−/− mice using Fisher’s exact test, and lesion multiplicity was compared using the
Mann-Whitney test. Statistical comparisons of all other endpoints between control and
Gpat1−/− mice were determined using unpaired, two-tailed, Student’s t-tests; p-values ≤ .05
were considered significant.
Results
GPAT Expression Profiles of Gpat1−/− Mice on Both the C57Bl/6 and C3H Strain
Backgrounds Were Similar
Gpat1 mRNA abundance was similar in control liver from C3H and C57Bl/6 strains (Figure
1A). Compared with controls, Gpat1 mRNA abundance in Gpat1−/− liver was reduced 80–
90%, regardless of strain background. The mRNA expression of Gpat2, Gpat3, and Gpat4
did not increase in C3H Gpat1−/− livers, demonstrating lack of compensation by the three
other GPAT isoforms (Figure 1B). The activities of GPAT2, 3, and 4, but not GPAT1, are
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inhibited by sulfhydryl reagents like NEM. NEM-sensitive GPAT activity in the liver was
similar in control and Gpat1−/− mice, whereas NEM-resistant GPAT activity (GPAT1
activity) was 85% lower than in control mice (Figure 1C). Thus, the extent of Gpat1
knockout in the liver was similar in mice on the C57BL/6 and the C3H strain backgrounds.
Gpat1−/− Mice Were Less Susceptible to DEN-Induced Liver Tumorigenesis
Tumorigenesis was initiated by treating Gpat1−/− and control mice on the C3H background
with a single injection of the mutagenic carcinogen, DEN, on day 15 of age. Tumorigenesis
was then promoted with phenobarbital supplied in the drinking water until the mice were 21
or 34 weeks old. Weight gain did not differ between the genotypes (data not shown). At
necropsy, macroscopically visible, tan nodules present on the surface of the liver and lungs
were quantified. Compared with controls treated with DEN and phenobarbital, the average
number of macroscopic foci per liver was 93% lower in Gpat1−/− mice at 21 weeks of age
and 39% lower at 34 weeks of age (Figure 2A). The average number of macroscopic foci in
control and Gpat1−/− mice per liver was 27 versus 2 foci and 65 versus 40 foci at 21 and 34
weeks of age, respectively. Of the four liver lobes, the left and median lobes contained the
largest number of visible macroscopic foci in both genotypes. At 34 weeks of age compared
to control mice, a reduction in Gpat1−/− liver foci was noted for the left (58%), median
(37%), and right (58%) lobes (Figure 2B).
DEN treatment primarily affects liver tissue, but it can also induce primary proliferative
lesions (hyperplasias and/or neoplasms) in lung (Reznik-Schuller 1983). Overall, DEN
treatment induced relatively few macroscopic lung foci. The average number of
macroscopic foci observed per lung in control and Gpat1−/− mice was 0 versus 0.09 foci and
1 versus 0.87 foci at 21 and 34 weeks of age, respectively. No differences between
genotypes were found either in the macroscopic incidence or the average number of foci per
lung between wildtype and Gpat1−/− mice (data not shown). Microscopically, a few of the
lesions were identified as either focal alveolar epithelial (type II pneumocyte) hyperplasia or
alveolar/ bronchiolar adenomas. The lack of genotype difference in the development of lung
foci is consistent with the relatively low activity of GPAT1 (mitochondrial GPAT) in lung
(Schlossman and Bell 1977; Das and Haldar 1987).
Microscopic evaluation of representative liver sections from control and Gpat1−/− mice
supported the overall decrease in hepatocellular proliferative lesions (FAH and neoplasms)
in Gpat1−/− mice. Four types of foci were identified (Table 1). In both genotypes the
majority of the examined liver foci at 21 weeks were basophilic (Figure 5 and Table 1).
Basophilic foci are highly proliferative and associated with the development of HCC in rats
fed the PPARα ligand Wy-14,643 (Marsman and Popp 1994). At 34 weeks, themajority of
foci evaluated were of mixed type. Gpat1−/− mice at 21 weeks had developed fewer foci
overall (p < .05), decreased basophilic and eosinophilic foci, but little or no difference in the
number of mixed and clear foci. Similarly, at 34 wks, Gpat1−/− mice had developed fewer
basophilic foci (p < .05) and decreases in eosinophilic and mixed foci. In contrast, Gpat1−/−
mice developed a greater number of clear foci than did control mice (p < .05).Clear cell
FAH are often found to have increased cytoplasmic glycogen with or without lipid,
indicating possible dysfunctional cellular metabolism.
Representative liver sections from control and Gpat1−/− mice were evaluated
microscopically for the incidence of primary HCC and hepatocellular adenomas in livers
and for lung metastases (Table 1). At 21 weeks, 17 adenomas were detected in 50%of
control mice (multiplicity = 4.3), whereas no adenomas were present in the Gpat1−/− mice
(Table 1, p < .05). At 34 weeks, adenomas were present in 100% of control mice and in 93%
of Gpat1−/− mice, whereas HCCs were observed in 13% of control mice and in only 6% of
Gpat1−/− mice. Tumor multiplicity (the number of liver neoplasms per tumor-bearing
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animals) was similar in both groups. No tumor metastases were found in representative lung
sections of either genotype.
Rates of Hepatocyte Proliferation Were Higher in Gpat1−/− Mice
Our data demonstrate that Gpat1−/− mice on the C3H back-ground were less susceptible to
DEN-induced liver tumorigenesis. We previously reported that Gpat1−/− mice on the C57Bl/
6 background have increases in both apoptosis and proliferation, suggesting that the
increased rate of hepatocyte turnover might result in a lower susceptibility to liver cancer
(Hammond et al. 2007). We examined the rate of cell proliferation in 8 week old Gpat1−/−
mice to verify that the increased rates of proliferation observed in Gpat1−/− mice on the
C57Bl/6 background were preserved in the C3H background. Compared to controls, the rate
of cell proliferation, assessed by BrdU incorporation into hepatocytes during a 48 h
exposure, was approximately 2-fold higher in Gpat1−/− livers (Figure 3), although liver
weights were unchanged. These data suggest that increased hepatocyte turnover in Gpat1−/−
livers reduced the survival of aberrant, tumorigenic cells.
GPAT1 Was Not Critical for PPARα-Mediated Induction of Hepatocellular Proliferation
PPARα increases the numbers of both peroxisomes and mitochondria and upregulates
mitochondrial genes involved in lipid metabolism (Bogacka et al. 2005). Because
supplementation with the PPARα agonist Wy-14,643 promotes hepatocellular proliferation
and can promote cancer by decreasing the expression of the microRNA let-7c gene, thereby
allowing proliferative c-myc to remain active (Gonzalez and Shah 2008), we asked whether
GPAT1 was required for the ability of PPARα to increase the rate of hepatocyte
proliferation. Wy-14,643 treatment increased liver weight, as a percentage of body weight,
by 2.4-fold in control mice and 2-fold in Gpat1−/− mice (Figure 4A). The rates of BrdU
incorporation into hepatocytes during a 72-h period in Wy-treated mice, compared with
vehicle-treated mice, increased 10-fold in both the control and Gpat1−/− mice (Figure 4B).
Thus, GPAT1 was not critical for PPARα-mediated induction of hepatocellular
proliferation.
Discussion
The development of HCC is often preceded by hepatitis C infection, hepatitis B infection,
aflatoxin B1 intoxication, or NASH. NASH develops in association with a high-fat diet and
obesity. With the dramatic worldwide increase in the incidence of obesity and NASH, the
WHO has predicted that as many as 2 million of the currently obese individuals will develop
cirrhosis that may progress to HCC (Schreuder et al. 2008). Although HCC develops as part
of the natural progression of NASH, the role of complex lipid synthesis in HCC
development remains unresolved. In patients with chronic hepatitis C infection, hepatic
steatosis is an independent risk factor (Ohata et al. 2003), likely due to the requirement of
lipid droplets for viral propagation (Herker and Ott 2011). Hepatic steatosis increases the
risk of HCC in several mouse models. For instance, the typically HCC-resistant C57Bl/6
mice develop NASH and HCC when fed a high (60%) fat diet (Hill-Baskin et al. 2009), and
after HCC induction with a high dose of DEN, both dietary and genetic obesity enhance
hepatic tumorigenesis in C57Bl/6 mice (Park et al. 2010). In another model, hepatic steatosis
induced by a choline-deficient diet plus methionine in the drinking water or induced by a
choline-deficient L-amino acid-defined diet caused HCC in 100% of mice within one year of
beginning the diet (Fausto and Campbell 2010). These data show a strong link between diet,
fatty liver, and risk of liver tumorigenesis.
Another mouse model of hepatic steatosis is the hepatocyte-specific deficiency of the
phosphatase and tensin homolog (PTEN), an inhibitor of PI3 kinase. These PTEN−/− mice
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have activated Akt (serine/threonine protein kinase) and MAPK (mitogen-activated protein
kinase), steatohepatitis, and an increase in hepatocellular carcinomas (Horie et al. 2004;
Watanabe et al. 2007). In mice that overexpress platelet-derived growth factor-C (PDGF-C)
(Campbell et al. 2005), 80% develop hepatic steatosis that progresses to fibrosis and stellate
cell activation; activated stellate cells produce matrix and factors that stimulate hepatocytes
to proliferate and generate chemokines that attract inflammatory cells (Jou, Choi, and Diehl
2008). By 12 months, the hepatosteatotic PDGF-C transgenic mice develop HCC. Like
PTEN−/− mice, the PDGF-C transgenic mice also have activated growth factor-mediated
signaling pathways that include extracellular-regulated kinases-1 and -2 (ERK1 and 2) and
AKT. The overexpression of another growth factor, fibroblast growth factor 21 (Fgf21) in
the liver attenuates DEN-induced HCC (Huang, Yu, Jin, Yang, et al. 2006), suggesting that
not all growth factor-stimulated pathways increase HCC development. Conversely, the liver-
specific overexpression of the fibroblast growth factor receptor 1 (FGFR1) increases DEN-
induced HCC (Huang, Yu, Jin, Kobayashi, et al. 2006), although FGFR1 knockout mice are
not protected from DEN-initiated HCC (Huang, Yu, Jin, Yang, et al. 2006), suggesting that
this signaling pathway can influence, but is not required for DEN-initiated HCC. Taken as a
whole, these data suggest that HCC development is associated with specific growth factors
that stimulate hepatocyte proliferation in the presence of obesity and hepatic steatosis.
Consistent with the role of GPAT in initiating the synthesis of TAG, compared with wild-
type mice, Gpat1−/− mice synthesize and store less hepatic TAG and shunt more fatty acid
toward oxidation (Hammond et al. 2005). Thus, after Gpat1−/− mice were fed a high-fat diet
for 4 months, their livers contained 60% less fat than those of wildtype controls (Hammond
et al. 2005); and, compared with ob/ob mice, double knockout ob/ob-Gpat−/− mice have a
59% reduction in hepatic TAG content (Wendel et al. 2010). Compared with controls, the
content of acyl-CoA is higher in Gpat1−/− liver, whereas liver content of the signaling lipids,
lysophosphatidic acid, and diacylglycerol, is lower (Neschen et al. 2005). Because GPAT1,
which acylates the sn-1 position of glycerolipids, has a strong preference for saturated fatty
acyl-CoAs, particularly palmitoyl-CoA (Coleman and Lee 2004), the content of palmitate in
Gpat1−/− liver phosphatidylcholine and phosphatidylethanolamine is diminished at the sn-1
position (Hammond et al. 2002). As a result of the decrease in palmitate, these
phospholipids contain relatively more 18:1 (oleate) at the sn-1 position and more 20:4ω6
(arachidonate) at the sn-2 position. Gpat1−/− livers contain more 4-hydroxy-2-nonenal, a
deleterious product of 20:4ω6 peroxidation that occurs with oxidative stress, as well as
increased rates of hepatocyte apoptosis and proliferation (Hammond et al. 2007). Thus,
Gpat1−/− livers exhibit both reduced synthesis of TAG and an increased rate of cell turnover.
In mice, PPARα up-regulates genes that enhance hepatocyte proliferation; the resulting
selective clonal expansion may lead to tumorigenesis (Klaunig et al. 2003). Although PPAR
transcriptional activity regulates genes of lipid metabolism, we failed to find a requirement
for GPAT1-mediated lipid synthesis and PPARα agonist-mediated hepatocyte proliferation.
Hepatitis C-induction of HCC in mice is enhanced by liver-specific overexpression of
PPARα and by exposure to PPARα agonists, suggesting that PPARα is critical for hepatitis
C-induction of HCC (Tanaka et al. 2008). Our data, however, suggest that glycerolipid
synthesis via the Kennedy pathway does not alter PPARα-mediated hepatocyte
proliferation. Because chronically activated PPARα results in hepatic tumors in rodents,
endogenous ligands like long-chain fatty acids or their metabolitesmight contribute to
hepatic carcinogenesis (Yu, Rao, and Reddy 2003), but this is unlikely to occur in Gpat1−/−
mice. Acyl-CoA content is 64% higher in livers with deficient GPAT1 (Neschen et al.
2005); thus, Gpat1−/− livers might have increased acyl-CoAs that enter mitochondrial or
extra-mitochondrial pathways that increase oxidative stress and thereby alter either gene
expression or DNA itself (Ockner, Kaikaus, and Bass 1993). In fact, livers from Gpat1−/−
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mice do exhibit increased oxidative stress (Hammond et al. 2007) although they proved to
be less susceptible to chemically-induced tumorigenesis.
Compared to wildtype C3H mice, Gpat1−/− mice had fewer DEN-induced hepatic foci,
adenomas, and HCC. At 21 and 34 weeks, Gpat1−/− livers contained fewer preneoplastic
foci and tumors. This decreased susceptibility suggests that the absence of GPAT1 causes
metabolic and biochemical alterations in mouse livers that diminish its carcinogenic risk.
These alterations may include the propensity of Gpat1−/− mice to resist hepatic steatosis in
both diet and genetic models (Hammond et al. 2005; Wendel et al. 2010). Mice deficient in
GPAT1 were protected from HCC despite increases in both proliferation and measures of
oxidative stress (Hammond et al. 2007). As was shown in Gpat1−/− livers on the C57Bl/6
background, the absence of GPAT1 in the C3H strain resulted in a 2-fold greater BrdU
incorporation than occurred in wildtype C3H livers. In a comparison of C3H and C3B6F1
(C3H×C57BL/6) mice in which tumors were induced with a regimen of 16 mg/kg DEN plus
500 p.p.m. sodium phenobarbital in drinking water and examined at 23 weeks, labeling with
BrdU increased in foci and adenomas; however, in unaffected or normal hepatocytes, the
level of BrdU incorporation did not correlate with the greatly increased number of tumors in
the C3H mice (Goldsworthy and Fransson-Steen 2002). Thus in Gpat1−/− liver, the increase
in ROS, the impaired mitochondrial function, and the increase in apoptosis may diminish the
propensity to develop liver tumors.
Exposure to the PPARα ligand WY-14,643 had similar effects on liver weight and BrdU
incorporation in control and Gpat1−/− liver, indicating that at baseline, the two genotypes did
not differ in their capacity for PPARα-mediated stimulation. Further, in both genotypes,
mRNA abundance is similar for PPARα itself, for peroxisome proliferator-activated
receptor-α coactivator-1, and for the PPARα target genes, acyl-CoA oxidase, carnitine
palmitoyltransferase-1, and long-chain acyl-CoA dehydrogenase (Hammond et al. 2005).
The toxicity associated with hepatic steatosis has been associated with excess fatty acid
metabolites that harm hepatocytes and render them unable to regenerate properly (Jou, Choi,
and Diehl 2008). However, unlike models in which steatosis and oxidative stress lead to cell
proliferation and HCC, Gpat1−/− mice are resistant to both diet-induced and genetic
steatosis, but have up-regulated fatty acid oxidation, and an increased rate of hepatocyte
proliferation (Hammond et al., 2007, Wendel et al., 2010) that is associated with reduced
susceptibility to tumorigenic foci and adenomas. It is as yet unclear as to whether the
increase in hepatocyte turnover or the lack of a toxic lipid metabolite protected the Gpat1−/−
mice from tumorigenesis. This relative protection could provide clues as to the underlying
pathogenesis of HCC.
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PPAR peroxisome-proliferator activated receptor
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Gpat1−/− mice on the C3H strain background had decreased Gpat1 expression and activity in
liver. (A) Gpat1 mRNA abundance in C57Bl/6 and C3H control livers. (B) Gpat2, Gpat3,
and Gpat4 mRNA abundance in control and Gpat1−/− livers on the C3H background. (C)
GPAT-specific activity in control and Gpat1−/− livers on the C3H background. Data
represent the average ± SEM; *p ≤ .05, **p ≤ .01, ***p ≤ .001, between genotypes.
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Gpat1−/− mice had reduced susceptibility to liver cancer. (A) Average number of
macroscopically visible liver nodules in control and Gpat1−/− 21-week-old mice (control, n
= 12; Gpat1−/−, n = 11) and 34-week-old mice (control, n = 15; Gpat1−/−, n = 19). (B)
Average of macroscopically visible nodules per liver lobe at 34 wk of age (n = 15). Data
represent the average ± SEM; *p ≤ .05, **p ≤ .01, between genotypes.
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Gpat1−/− livers from 8-week-old, non-DEN-exposed mice had increased rates of hepatocyte
proliferation. Percentage of hepatocytes positive for BrdU incorporation after a 48-h
exposure.
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Gpat1−/− and control hepatocytes increased BrdU incorporation similarly in response to
Wy-14643. (A) Liver weight, as a percentage of body weight; and (B) BrdU incorporation
into hepatocytes in control and Gpat1−/− mice with or without (No Trt) 1 wk of exposure to
Wy-14643, n = 3. Data represent the average ± SEM; #, p ≤ .05 between no treatment and
Wy-14643–treated mice within the genotype.
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Representative photomicrographs of lesions in C3H livers. (A) Hematoxylin and eosin-
stained basophilic focus of altered hepatocytes; (B) clear cell focus of altered hepatocytes;
(C) low magnification of an hepatocellular adenoma; (D) high magnification of an
hepatocellular carcinoma characterized by pleomorphic hepatocytes forming irregular
trabeculae that are often three cells or greater in width.
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